Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease

jpedsurg.org

Modified monoclonal class-G immunoglobulins (IgG) have been shown to protect infants from respiratory syncytial virus (RSV), a prevalent disease with particularly high morbidity in newborns. We sought to determine whether a clinically relevant monoclonal IgG against RSV could be delivered to the fetus via transammiotic fetal immunotherapy (TRAFIT) and remain bioavailable after birth.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Aug 2025 · 1 min read

In brief

This study explores transamniotic fetal immunotherapy (TRAFIT) as a novel prenatal delivery method for RSV-specific monoclonal antibodies, aiming to provide passive immunity against respiratory syncytial virus before birth. Researchers investigated whether therapeutic IgG administered to the fetus in utero maintains protective levels after delivery, potentially offering a preventive strategy for high-risk newborns.

Modified monoclonal IgG antibodies can protect infants from RSV, which causes high morbidity in newborns.
Transamniotic fetal immunotherapy (TRAFIT) may enable prenatal delivery of anti-RSV monoclonal antibodies to the fetus.
Study investigates whether prenatally delivered anti-RSV IgG remains bioavailable after birth for neonatal protection.
Novel prenatal immunization strategy could prevent RSV disease in high-risk newborns before postnatal exposure.

Written by the GCMD Library team from the article.

Read it at the source ↗